CSII - カ―ディオバスキュラ―・システムズ (Cardiovascular Systems Inc.) カ―ディオバスキュラ―・システムズ

 CSIIのチャート


 CSIIの企業情報

symbol CSII
会社名 Cardiovascular Systems Inc (カ―ディオバスキュラ―・システムズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 カーディオバスキュラー・システムズ(Cardiovascular Systems Inc.)は、医療技術会社であり、動脈カルシウムを含む末梢・冠動脈疾患に罹患する患者の治療に従事する。同社は、末梢・冠状動脈の両方の商用アプリケーションに、軌道アテローム切除技術を開発する。末梢動脈疾患(PAD)システムは、膝の上下の脚動脈におけるプラークタイプを治療できるカテーテルベースのプラットフォームである。同社の主力製品には、「Diamondback 360 Peripheral Orbital Atherectomy System」(OAS) (Diamondback 360 Peripheral)、「Stealth 360 OAS」(Stealth 360)、「Diamondback 360 Peripheral」、「Diamondback 360 60cm Peripheral」、「Diamondback 360 Low Profile Peripheral」、「Diamondback 360 1.50 Peripheral」及び「Diamondback 360 2.00 Peripheral」がある。同社の冠状動脈疾患(CAD)製品である「Diamondback 360 Coronary OAS」(Coronary OAS)は、重度石灰化冠状動脈の治療薬として販売される。   カ―ディオバスキュラ―・システムズは、米国の医療機器メ―カ―。血管疾患のためのインタ―ベンション治療システムの開発と商業化に焦点を当てる。末梢動脈疾患の製品、ステルス360パッドシステム、ダイヤ360パッドシステム、およびプレデタ―360パッドシステムは、カテ―テルベ―スのプラットフォ―ムで、脚の石灰化冠状動脈の治療法として使用される。   
本社所在地 1225 Old Highway 8 Northwest St. Paul MN 55112-6416 USA
代表者氏名 Scott R. Ward スコットR.ワード
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 651-259-1600
設立年月日 2000年
市場名 NASDAQ National Market System
ipoyear 1981年
従業員数 652人
url www.csi360.com
nasdaq_url https://www.nasdaq.com/symbol/csii
adr_tso
EBITDA EBITDA(百万ドル) 5.96400
終値(lastsale) 36.45
時価総額(marketcap) 1265033663.55
時価総額 時価総額(百万ドル) 1262.951
売上高 売上高(百万ドル) 217.04300
企業価値(EV) 企業価値(EV)(百万ドル) 1167.211
当期純利益 当期純利益(百万ドル) 1.71200
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Cardiovascular Systems Inc revenues increased 6% to $217M. Net income totaled $1.7M vs. loss of $1.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Stock-based Compensation in R&D decrease of 4% to $967K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.06 to $0.05.

 CSIIのテクニカル分析


 CSIIのニュース

   Cardiovascular Systems, Inc. to Participate at Four Upcoming Investor Conferences  2021/02/11 12:00:00 Business Wire
CSII Q3 Conferences
   Cardiovascular Systems (CSII) Set to Announce Quarterly Earnings on Wednesday  2021/02/02 07:18:40 Transcript Daily
Cardiovascular Systems (NASDAQ:CSII) is scheduled to post its quarterly earnings results after the market closes on Wednesday, February 3rd. Analysts expect Cardiovascular Systems to post earnings of ($0.07) per share for the quarter. Cardiovascular Systems has set its Q2 2021 After-Hours guidance at EPS.Individual that wish to listen to the company’s earnings conference call can […]
   Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology - Stocks News Feed  2021/02/01 12:00:00 Stocks News Feed
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This partnership brings together CSI’s leadership in the treatment of calcified arterial lesions with Dr. Philippe Marco, a pioneer in the successful development of… Read More »Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology
   Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System - Stocks News Feed  2021/01/18 21:05:00 Stocks News Feed
One solution to both reduce surface calcium and fracture deep calcium ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has received CE Mark for its Diamondback 360® Coronary Orbital Atherectomy System… Read More »Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System
   Needham Stick to Their Buy Rating for Cardiovascular Systems  2020/11/05 11:45:59 Investing.com
Needham Stick to Their Buy Rating for Cardiovascular Systems
   Cardiovascular Systems, Inc. to Participate at Four Upcoming Investor Conferences  2021/02/11 12:00:00 Business Wire
CSII Q3 Conferences
   Cardiovascular Systems (CSII) Set to Announce Quarterly Earnings on Wednesday  2021/02/02 07:18:40 Transcript Daily
Cardiovascular Systems (NASDAQ:CSII) is scheduled to post its quarterly earnings results after the market closes on Wednesday, February 3rd. Analysts expect Cardiovascular Systems to post earnings of ($0.07) per share for the quarter. Cardiovascular Systems has set its Q2 2021 After-Hours guidance at EPS.Individual that wish to listen to the company’s earnings conference call can […]
   Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology - Stocks News Feed  2021/02/01 12:00:00 Stocks News Feed
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This partnership brings together CSI’s leadership in the treatment of calcified arterial lesions with Dr. Philippe Marco, a pioneer in the successful development of… Read More »Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology
   Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System - Stocks News Feed  2021/01/18 21:05:00 Stocks News Feed
One solution to both reduce surface calcium and fracture deep calcium ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has received CE Mark for its Diamondback 360® Coronary Orbital Atherectomy System… Read More »Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System
   Needham Stick to Their Buy Rating for Cardiovascular Systems  2020/11/05 11:45:59 Investing.com
Needham Stick to Their Buy Rating for Cardiovascular Systems
   Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System - Stocks News Feed  2021/01/18 21:05:00 Stocks News Feed
One solution to both reduce surface calcium and fracture deep calcium ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has received CE Mark for its Diamondback 360® Coronary Orbital Atherectomy System… Read More »Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System
   Needham Stick to Their Buy Rating for Cardiovascular Systems  2020/11/05 11:45:59 Investing.com
Needham Stick to Their Buy Rating for Cardiovascular Systems
   Cardiovascular Systems Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2020/11/04 16:30:00 Stock Market Daily
Cardiovascular Systems announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Q1 2022 Earnings Estimate for Cardiovascular Systems, Inc. (NASDAQ:CSII) Issued By SVB Leerink  2020/10/21 06:52:49 Dakota Financial News
Cardiovascular Systems, Inc. (NASDAQ:CSII) – Investment analysts at SVB Leerink reduced their Q1 2022 earnings per share (EPS) estimates for shares of Cardiovascular Systems in a note issued to investors on Thursday, October 15th. SVB Leerink analyst D. Antalffy now expects that the medical device company will earn ($0.19) per share for the quarter, down […]
   Cardiovascular Systems, Inc. (NASDAQ:CSII) Expected to Announce Quarterly Sales of $56.27 Million  2020/10/20 19:00:49 Transcript Daily
Wall Street analysts expect Cardiovascular Systems, Inc. (NASDAQ:CSII) to post $56.27 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Cardiovascular Systems’ earnings, with the highest sales estimate coming in at $57.53 million and the lowest estimate coming in at $55.00 million. Cardiovascular Systems posted sales of […]

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 カ―ディオバスキュラ―・システムズ CSII Cardiovascular Systems Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)